Faeth Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Faeth Therapeutics Stock-Based Compensation Growth & History (FTH)
Faeth Therapeutics's stock-based compensation was $1.3M for fiscal 2025.
View full Faeth Therapeutics company overviewFaeth Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.3M | −$1.9M | −59.36% |
| 2024 | 2024-12-31 | $3.1M | −$1.3M | −29.61% |
| 2023 | 2023-12-31 | $4.5M | −$1.4M | −23.37% |
| 2022 | 2022-12-31 | $5.8M | $155,000 | +2.74% |
| 2021 | 2021-12-31 | $5.7M | $4.2M | +279.16% |
| 2020 | 2020-12-31 | $1.5M | — | — |
Faeth Therapeutics quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.5M | $4.2M | +1598.11% |
| Q1 2026 | 2026-03-31 | $12.9M | $12.4M | +2697.83% |
| Q4 2025 | 2025-12-31 | $295,000 | −$96,000 | −24.55% |
| Q3 2025 | 2025-09-30 | $254,000 | −$479,000 | −65.35% |
| Q2 2025 | 2025-06-30 | $264,000 | −$531,000 | −66.79% |
| Q1 2025 | 2025-03-31 | $461,000 | −$755,000 | −62.09% |
| Q4 2024 | 2024-12-31 | $391,000 | −$707,000 | −64.39% |
| Q3 2024 | 2024-09-30 | $733,000 | −$315,000 | −30.06% |
| Q2 2024 | 2024-06-30 | $795,000 | −$300,000 | −27.40% |
| Q1 2024 | 2024-03-31 | $1.2M | $3,000 | +0.25% |
| Q4 2023 | 2023-12-31 | $1.1M | −$301,000 | −21.52% |
| Q3 2023 | 2023-09-30 | $1.0M | −$431,000 | −29.14% |
| Q2 2023 | 2023-06-30 | $1.1M | −$324,000 | −22.83% |
| Q1 2023 | 2023-03-31 | $1.2M | −$302,000 | −19.93% |
| Q4 2022 | 2022-12-31 | $1.4M | $573,000 | +69.37% |
| Q3 2022 | 2022-09-30 | $1.5M | −$257,000 | −14.80% |
| Q2 2022 | 2022-06-30 | $1.4M | −$327,000 | −18.73% |
| Q1 2022 | 2022-03-31 | $1.5M | $166,000 | +12.31% |
| Q4 2021 | 2021-12-31 | $826,000 | $472,000 | +133.33% |
| Q3 2021 | 2021-09-30 | $1.7M | $955,000 | +122.28% |
| Q2 2021 | 2021-06-30 | $1.7M | $1.6M | +971.17% |
| Q1 2021 | 2021-03-31 | $1.3M | $1.2M | +595.36% |
| Q4 2020 | 2020-12-31 | $354,000 | — | — |
| Q3 2020 | 2020-09-30 | $781,000 | — | — |
| Q2 2020 | 2020-06-30 | $163,000 | — | — |
| Q1 2020 | 2020-03-31 | $194,000 | — | — |
Faeth Therapeutics stock-based compensation trends
Over the last five fiscal years, Faeth Therapeutics's stock-based compensation decreased from $1.5M to $1.3M, a change of −$218,000. The latest reported quarter, Q2 2026, shows $4.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Faeth Therapeutics source filings ↗